LOCATE  1 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCATE  
 
PROTOCOL  NUMBER:  BED003  
Version 4.0 Date: 07 June 2017  
 
 
The Impact  of 18F-fluciclovine  (FACBC)  PET/CT  on 
Management  of Patients  with  Rising  PSA  after  Initial  
Prostate  Cancer  Treatment  
 
PHASE  IIIb 
 
 
IND Number  : 107707  
Sponsor:  Blue  Earth  Diagnostics  
 
 
 
 
Confidential  
This document  is the property  of Blue Earth  Diagnostics  and may not – in full or in part – 
be passed  on, reproduced, published  or otherwise  used without  the express  permission  of 
Blue Earth  Diagnostics.  
 
 
LOCATE  2 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
Blue  Earth  Diagnostics   
 
Clinical  Research Protocol  
The Impact  of 18F-fluciclovine  (FACBC)  PET/CT  on Management  of Patients  with  Rising  PSA after  
Initial  Prostate  Cancer  Treatment  
 
 
Protocol Number:  BED003  
Version  / Date:  3.0/ May 23rd 2016 
Investigational  Product:  Fluciclovine  (18F) [referred  to as 18F-fluciclovine in this protocol]  
EUDRACT/IND  Number:   
Development  Phase:  Phase  IIIb 
Sponsor:  Blue Earth  Diagnostics  Ltd 
Unit F14 Oxford  Science  Park 
Magdalen  Centre  
Robert  Robinson  Avenue  
Oxford  OX4  4AG 
UK 
Tel: +44 1865  784186  
Funding  Organization:  Blue Earth  Diagnostics  
Study  Chair:  Umar  Mahmood,  MD, PhD 
Professor  of Radiology,  
Harvard  Medical  School  
Director,  Precision  Medicine,  Martinos  Center  for Biomedical  
Imaging  
Massachusetts  General  Hospital  
149 13th St, 2301 
Charlestown,  MA 02129  
Phone:  617-726-6477 
Fax: 617-726-7422 
Email:  umahmood@mgh.harvard.edu  
BED  Medical  Monitor:  Peter  Gardiner  MB ChB,  MRCP,  FFPM  
Blue Earth  Inc 
25 Burlington  Mall  Road  
Suite  404 
Burlington  MA USA  01803  
 
Telephone:  +1-978-502-9098 
E-mail:  p.gardiner@blueearthdx.com  
LOCATE  3 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
BED  Study  Statistician  
 Albert  Chau  
Blue Earth  Diagnostics  Ltd 
Oxford  Science  Park 
Magdalen  Centre  
Robert  Robinson  Avenue  
Oxford  OX4  4AG  
LOCATE  4 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
Study  Co-chairs  David  Mankoff,  MD, PhD 
Professor  of Radiology  
Chief,  Nuclear  Medicine  & Clinical  Molecular  Imaging  
University  of Pennsylvania  
116 Donner  Building  
Philadelphia,  PA 19104 -4283  
Phone:  215-615-3687  
Fax: 215-349-5843  
Email:   david.mankoff@uphs.upenn.edu  
 
Jonathan  McConathy,  MD, PhD  
University of Alabama - Birmin gham 
Director, Division of Molecular Imaging and Therapeutics  
Associate Professor, Division of Molecular Imaging and Therapeutics  
Email: jmcconathy@uabmc.edu  
Phone 205 -996-7115  
 
 
 
Philip  J. Saylor,  MD 
Massachusetts  General  Hospital  
Assistant  Professor,  Medicine  
55 Fruit  Street,  Yawkey  7E 
Boston,  MA 02114 -2696  
Phone:  617-643-1763  
Fax: 617-726-8685  
Email:  psaylor@partners.org  
 
David  Schuster,  MD 
Associate  Professor  
Director,  Division  of Nuclear  Medicine  and Molecular  Imaging  
Emory  University  Hospital  
1364  Clifton  Road  NE, Room  E152  
Atlanta,  GA 30322  
Phone:  404-712-4859  
Email: dschust@emory.edu 
 
Barry  A. Siegel,  MD 
Professor,  Radiology  and Medicine  
Chief,  Division  of Nuclear  Medicine  
Washington  University  School  of Medicine  
510 South  Kingshighway  Boulevard  
St. Louis,  MO 63110  
Phone:  314- 362-2809  
LOCATE  6 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
PROTOCOL  AGREEMENT  
 
 
I have  read the protocol  specified  below.  In my formal  capacity  as Investigator,  my duties  include  
providing  Blue  Earth  Diagnostics  with the information,  as outlined  in the protocol.  It is understood  that 
all information  pertaining  to the study  will be held strictly  confidential  and that this confidentiality  
requirement  applies  to all study  staff at this site. Furthermore,  on behalf  of the study  staff and myself,  I 
agree  to maintain  the procedures  required  to carry  out the study  in accordance  with accepted  GCP  
principles  and to abide  by the terms  of this protocol.  
 
 
Protocol Number:           BED003  Version  4.0 
 
 
Protocol Title:  The Impact  of 18F-fluciclovine  (FACBC)  PET/CT  on Management  of Patients  
with Rising  PSA after Initial Prostate  Cancer  Treatment  
 
 
Protocol Date:  07 June 2017  
 
 
 
 
 
____ -    
Investigator  Signature  Date  
 
 
 
 
 
Print  Name  and Title  
 
Site # 
 
 
 
Site Name  
 
 
 
Address  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Phone  Number  
 
 
LOCATE  7 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
CONTENTS  
LIST  OF ABBREVIATIONS  ................................ ................................ ................................ ........................... 10 
PROTOCOL  SYNOPSIS  ................................ ................................ ................................ ...........................  12 
1 BACKGROUND  ................................ ................................ ................................ ................................ ...... 17 
1.1 Overview  of Clinical  Studies  ................................ ................................ ................................ ...........  17 
2 STUDY  RATIONALE  ................................ ................................ ................................ .............................  18 
2.1 Risk-Benefit  Assessment ................................ ................................ ................................ ..................  19 
3 STUDY  OBJECTIVES  ................................ ................................ ................................ ............................  19 
3.1 Primary  Objective  ................................ ................................ ................................ .......................  19 
3.2 Secondary  Objectives  ................................ ................................ ................................ .......................  20 
4 STUDY  DESIGN  ................................ ................................ ................................ ...............................  20 
4.1 Study  Overview  ................................ ................................ ................................ ..........................  20 
5 CRITERIA  FOR EVALUATION  ................................ ................................ ................................ ...........  20 
5.1 Primary  Efficacy  Endpoint  ................................ ................................ ................................ ..........  20 
5.2 Secondary  Efficacy  Endpoints  ................................ ................................ ................................ .... 20 
5.3 Safety  Evaluations  ................................ ................................ ................................ ......................  21 
6 SUBJECT  SELECTION  ................................ ................................ ................................ .....................  21 
6.1 Study  Population  ................................ ................................ ................................ .........................  21 
6.2 Inclusion  Criteria  ................................ ................................ ................................ ........................  21 
6.3 Exclusion  Criteria  ................................ ................................ ................................ .......................  22 
7 CONCURRENT  MEDICATIONS  ................................ ................................ ................................ ..........  22 
7.1 Allowed  Medications  and Treatments  ................................ ................................ .........................  22 
7.2 Prohibited  Medications  and Treatments  ................................ ................................ ..........................  22 
8 STUDY  TREATMENTS  ................................ ................................ ................................ ....................  22 
8.1 Formulation  of Test Product  ................................ ................................ ................................ ....... 22 
8.2 Packaging  and Labeling  ................................ ................................ ................................ ..............  23 
8.3 Supply  of Study  Drug  at the Site................................ ................................ ................................ . 23 
8.4 Dispensing  ................................ ................................ ................................ ................................ .. 23 
8.5 Administration  Instructions  ................................ ................................ ................................ .......... 23 
8.6 Study  Drug  Accountability  ................................ ................................ ................................ .......... 23 
9 STUDY  PROCEDURES  AND  GUIDELINES  ................................ ................................ ......................  24 
9.1 Informed  Consent  ................................ ................................ ................................ .......................  24 
9.2 Clinical  Assessments  ................................ ................................ ................................ ........................  24 
LOCATE  8 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
 10 EVALUATIONS  BY VISIT  ................................ ................................ ................................ ................. 26 
10.1 Visit  1 - Screening  ................................ ................................ ................................ ....................... 26 
10.2 Enrollment  and PET/CT  Preparation  ................................ ................................ ........................... 26 
10.3 Visit  2 – 18F-fluciclovine  PET-CT ................................ ................................ ............................... 27 
10.4 Visit  3 - Telephone  Consultation  at 24 +/- 4 hours after  dosing ................................ ................... 27 
10.5 Documentation  of Management  plan revision  post 18F-fluciclovine  PET/CT  Scan  (2-22 days 
following  the scan)  ................................ ................................ ................................ ................................ ..27 
10.6 End of Study  (26+/ -4 weeks  post scan)  ................................ ................................ ........................ 28 
10.7 Off Study  Criteria  ................................ ................................ ................................ ........................ 28 
10.8 Discontinuation/Withdrawal  of Subjects ................................ ................................ ...................... 28 
10.9 Replacement  of Subjects  ................................ ................................ ................................ .............  28 
11 IMAGING  PROTOCOL  ................................ ................................ ................................ .................  29 
11.1 PET/CT  Scanner  ................................ ................................ ................................ ...............................  29 
11.2 18F-fluciclovine  injection  administration  ................................ ................................ ...................... 29 
11.3 18F-fluciclovine  PET/CT  acquisition  ................................ ................................ ............................ 29 
11.4 Image  Transfer  ................................ ................................ ................................ ............................. 29 
11.5 18F-fluciclovine  image  analysis  ................................ ................................ ................................ ......... 29 
12 ADVERSE  EVENT  REPORTING  AND  DOCUMENTATION  ................................ ....................... 29 
12.1 Adverse  Events  ................................ ................................ ................................ ................................ ..29 
12.2 Serious  Adverse  Event  (SAE)  ................................ ................................ ................................ ......31 
12.3 Medical  Monitoring  ................................ ................................ ................................ ....................  32 
13 PROTOCOL  VIOLATIONS  ................................ ................................ ................................ ...............  32 
14 STATISTICAL  METHODS  AND  CONSIDERATIONS  ................................ ................................ . 32 
14.1 Analysis  of Primary  Endpoint  ................................ ................................ ................................ .........  32 
14.2 Analysis  of Secondary  Endpoints  ................................ ................................ ...............................  33 
14.3 Interim  Analysis  ................................ ................................ ................................ ..........................  33 
14.4 Sample  Size and Randomization  ................................ ................................ ................................ ..33 
15 DATA  COLLECTION,  RETENTION  AND  MONITORING  ................................ ........................... 34 
15.1 Data Collection  Instruments ................................ ................................ ................................ ......... 34 
15.2 Data Management  Procedures  ................................ ................................ ................................ .....34 
15.3 Data Quality  Control  and Reporting  ................................ ................................ ...........................  34 
15.4 Archiving  of Data  ................................ ................................ ................................ .......................  34 
15.5 Availability  and Retention  of Investigational  Records  ................................ ................................ ... 35 
LOCATE  9 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
 15.6 Monitoring  and Auditing  ................................ ................................ ................................ ............. 35 
15.7 Subject  Confidentiality  ................................ ................................ ................................ ................ 35 
16 ADMINISTRATIVE,  ETHICAL,  REGULATORY  CONSIDERATIONS  ................................ ....35 
16.1 Protocol  Amendments  ................................ ................................ ................................ ....................... 35 
16.2 Institutional  Review  Boards  and Independent  Ethics  Committees  ................................ .............. 35 
16.3 Informed  Consent  Form  ................................ ................................ ................................ ............... 36 
16.4 Publications ................................ ................................ ................................ ................................ ..36 
16.5 Investigator  Responsibilities  ................................ ................................ ................................ ............. 36 
17 REFERENCES  ................................ ................................ ................................ ................................ 38 
LOCATE  10 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
LIST  OF ABBREVIATIONS  
 
ACRIN  American  College  of Radiology  Imaging  Network  
AAT  Amino  acid transporters  
AE Adverse  event  
ADT  Androgen  Deprivation  Therapy  
ALT  Alanine  aminotransferase  
AST Aspartate  aminotransferase  
BED  Blue Earth  Diagnostics  
BUN  Blood  urea nitrogen  
CFR  Code  of Federal  Regulations  
C.I. Confidence  Interval  
CRF  Case  report  form  
CT Computerized  Tomography  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
DMC  Data Management  Center  
DR Detection  Rate 
ECG  Electrocardiogram  
eCRF  Electronic  Case  Report  Form  
EDC  Electronic  Data Capture  
FACBC  Fluciclovine  (18F) [referred  to as 18F-fluciclovine in this protocol]  
FDA  Food  and Drug  Administration  
GCP  Good  Clinical  Practice  
HIPAA  Health  Insurance  Portability  and Accountability  Act of 1996  
ICF Informed  consent  form  
ICH International  Conference  on Harmonization  
IEC Independent  Ethics  Committee  
INR International  normalized  ratio 
IRB Institutional  Review  Board  
IV Intravenous  
LDH  Lactate  dehydrogenase  
MEq  Milliequivalent  
MCH  Mean  Corpuscular  Hemoglobin  
MCHC  Mean  Corpuscular  Hemoglobin  Concentration  
LOCATE  11 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
mCi Millicurie  
MCV  Mean  Corpuscular  Volume  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MRI  Magnetic  resonance  imaging  
mSv Millisieverts  
NPV  Negative  predictive  value  
PET Positron  Emission  Tomography  
PET/CT  Positron  Emission  Tomography  with Computerized  Tomography  
PI Principal  Investigator  
PPV Positive  Predictive  Value  
PK Pharmacokinetic  
PSA Prostate  Specific  Antigen  
PSADT  Prostate  Specific  Antigen  Doubling  Time  
SAE Serious  Adverse  Experience  
SGOT  Serum  Glutamic  Oxaloacetic  Transaminase  
SGPT  Serum  Glutamic -Pyruvic  Transaminase  
SOP Standard  Operating  Procedure  
SPECT  Single  Photon  Emission  Computed  Tomography  
TNM  TNM  Classification  of Malignant  Tumors  
US Ultrasonograph  
LOCATE  12 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
PROTOCOL  SYNOPSIS  
 
 
 
TITLE  The Impact  of 18F-fluciclovine  (FACBC)  PET/CT  on Management  of 
Patients  with Rising  PSA after Initial Prostate  Cancer  Treatment  
SPONSOR  Blue Earth  Diagnostics  
FUNDING  
ORGANIZATION  Blue Earth  Diagnostics  
NUMBER  OF SITES  20 
RATIONALE  18F-fluciclovine   PET/CT  has  the potential   to  improve  medical   care and 
quality  of life among  men with prostate  cancer  in several  ways.  First,  
identification  of disease  in the prostate  bed and/or  regional  nodes  would  
provide  evidence  in support  of salvage  radiation  treatment,  and help to plan 
radiotherapy.  In addition,  the absence  of distant  disease  by 18F-fluciclovine  
PET/CT  in patients  would  preserve salvage local  therapy  as a clinical  option  
beyond  the time typically  offered.  Second,  identification  of distant  disease  at 
the time of consideration  of salvage  radiation  therapy  would  allow  patients  
to forego  radiation  that would  ultimately  be futile.  This would  spare  those  
patients  radiation -induced  side effects  such as impaired  recovery  of 
continence,  impaired  recovery  of erectile  function,  and diarrhea.  Finally,  the 
absence  of disease  detection  on a sensitive  imaging  modality  in patients  with 
a rising  PSA would  have the potential  to delay  initiation  of systemic  
androgen  deprivation  therapy,  a treatment  strategy  that causes  a number  of 
morbid  side effects  that are detrimental  to quality  of life. 
STUDY  DESIGN  This is a prospective  phase  IIIb study  to assess  the impact  on patient  
management  of 18F-fluciclovine  PET/CT  in patients  with rising  prostate  
specific  antigen  (PSA)  after initial  prostate  cancer  treatment.  
PRIMARY  OBJECTIVE  To measure  the fraction  of patients  for whom 18F-fluciclovine  PET/CT  alters  
intended  management  through  detection  of disease  after curative -intent  
treatment  in a population  of men with elevated  PSA levels  indicative  of 
persistent  or recurrent  prostate  cancer  and negative  or equivocal  findings  on 
standard -of-care diagnostic  imaging  tests. 
LOCATE  13 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
SECONDARY  
OBJECTIVES  1. To measure  the fraction  of patients  for whom  18F-fluciclovine  
PET/CT  leads  to a change  of actual  management  by comparison  
with intended  management  plan before  18F-fluciclovine  PET/CT.  
2. To estimate  the fraction  of patients  in whom  18F-fluciclovine  
PET/CT  yields  evidence  of recurrent  disease  on the basis  of imaging  
results.  
3. To estimate  1) the rates of detecting  regionally  recurrent  disease  
(i.e., prostatic  bed-only and/or  pelvic  disease  outside  of the bed) and 
2) the rate of detecting  distant  metastases  (i.e., bone  metastases,  
visceral  metastases,  or non-regional  nodal  metastases)  with 18F- 
fluciclovine  PET/CT  in the study  population.  
4.  To determine  1) the Positive  Predictive  Value  (PPV)  of 18F- 
fluciclovine  PET/CT  to detect  regionally  recurrent  disease  and 2) the 
PPV of 18F-fluciclovine  PET/CT  to detect  distant  metastases  in the 
study  population  in patients  who undergo  optional  biopsy  of 18F- 
fluciclovine  PET/CT  findings  or have documentation  of disease  
status  based  on other  imaging  and/or  follow -up data. 
5.   To explore  differences  in estimated  cost of treatment  plans  
determined  prior  to and following  18F-fluciclovine  PET/CT  
NUMBER  OF 
SUBJECTS  330 patients  
SUBJECT  SELECTION  
CRITERIA  Study  Population  
Patients  with suspicion  of recurrent  prostate  carcinoma  after presumed  
definitive  therapy  for primary disease  
Inclusion  Criteria : 
 History  of histologically  confirmed  adenocarcinoma  of the prostate  
post curative -intent  local  treatment  (radical  prostatectomy,  local  
radiotherapy,  brachytherapy).  
 Suspicion  of recurrent  prostate  carcinoma  after previous  presumed  
definitive  therapy  for primary disease  defined  as : 
o Post-prostatectomy  (with/without  adjuvant  RT):  Detectable  
or rising  PSA level  that is >0.2 ng/mL  with a second  
confirmatory  level  of   >0.2 ng/mL  
o Post radiotherapy  (without  RP): PSA rise ≥2ng/mL  over 
nadir 
 Negative  or equivocal  findings  on standard -of-care imaging  for 
restaging  of disease  in the previous  60 days:  Standard -of care 
imaging  is defined  as: 
LOCATE  14 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 o Whole -body  99mTc -MDP  bone  scintigraphy  or NaF PET -CT 
(dependent on standard of care at the institution )  and 
o Either  CT or MRI of the pelvis  (or the abdomen  and pelvis).  
 Being  considered  for salvage  therapy  
 Any non-surgical  local  treatment  such as previous  cryotherapy,  
external  beam  radiation,  or HiFU  must  have occurred  at least 1 year 
in the past. 
 Previous  brachytherapy  treatment  will have  occurred  at least 2 years  
in the past 
 Ability  to understand  and the willingness  to sign a written  informed  
consent  
Exclusion  Criteria : 
 Ongoing  treatment  with any systemic  therapy  intended  for the 
treatment  of prostate  cancer  (e.g.,  antiandrogen  or LHRH  agonist  or 
antagonist)  
 Androgen  deprivation  therapy  (ADT)  in the past 3 months  
 History  of bilateral  orchidectomy  
 Inability  to tolerate  18F-fluciclovine  PET/CT  
TEST  PRODUCT,  
DOSE,  AND  ROUTE  OF 
ADMINISTRATION  All subjects  will receive  a single  intravenous  dose of 10mCi  (370MBq)  
+20%18F-fluciclovine immediately  prior  to PET scan.  
There  will be no  repeat  dosing  
DURATION  OF SUBJECT  
PARTICIPATION  AND  
DURATION  OF STUDY  Patients  will be imaged  with 18F-fluciclovine  PET/CT  prior to planned  
treatment.  Follow -up for treatment  outcome  and results  of standard -of-care 
investigations  for up to 6 months  after 18F-fluciclovine  PET/CT.  
CONCOMITANT  
MEDICATIONS  Allowed : 
All treatments  except  for those  specifically  prohibited  
Prohibited : 
Ongoing  treatment  with any systemic  therapy  intended  for the treatment  of 
prostate  cancer  (e.g.,  antiandrogen  or LHRH  agonist  or antagonist),  
including  bilateral  orchiectomy  at time of screening  or scanning  
Efficacy  Evaluations   
Primary  endpoint  Change  to management  plan assessed  by comparing  Pre-18F-fluciclovine  
PET/CT  management  plan with Post-18F-fluciclovine  PET/CT  management  
plan. 
Secondary  endpoint  1.   Per-patient  impact  (yes/no)  of 18F-fluciclovine  PET/CT  on pre-PET 
intended  versus  post-PET actual  patient  management.  
LOCATE  15 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 2. The rate of detection  of any disease  site by 18F-fluciclovine  PET/CT  
in the study  population.  
3. The rate of detection  of 1) prostatic  bed and other  pelvic disease  and 
2) distant  metastases  (i.e., bone metastases,  visceral  metastases,  or 
non-regional  nodal  metastases)  with 18F-fluciclovine  PET/CT  in the 
study  population.  
4. The PPV of 18F-fluciclovine  PET/CT  to detect  regionally  recurrent  
disease  compared  to biopsy  in those  patients  who undergo  a regional  
disease  biopsy  on the basis  of a 18F-fluciclovine  PET/CT  finding  or 
in case of bony  disease  a correlation  with MRI or biopsy.  
5. The PPV of 18F-fluciclovine  PET/CT  to detect  distant  disease  
compared  to biopsy  in those  patients  who undergo  a distant  disease  
biopsy  on the basis  of a 18F-fluciclovine  PET/CT  finding  or in case 
of bony  disease  a correlation  with MRI or biopsy.  
An independent  adjudication  panel  will review  and adjudicate  18F- 
fluciclovine  PET/CT  lesions  with biopsy  or MRI during  follow -up to 
assess  the PPV and, where  possible,  NPV,  sensitivity  and specificity.  
Rates  of disease  detection  (radiographic  only and confirmed  by 
pathology  or MRI)  will be described  
Safety  Evaluations  Monitoring  for adverse  events,  change  in EKGs  and routine hematology  and 
biochemistry  evaluations  taken  prior  to and following  receipt  of 18F- 
fluciclovine  
Planned  Interim  Analyses  An interim analysis of a subset of study results on all enrolled subjects may 
be subm tted for potential public p resentation prior to completion of all data 
collection and analyses. As trial design will not be modified as a result of this 
interim analysis, no adjustment to the type I error is required . 
STATISTICS 
Primary  Analysis  Plan For the evaluation  of the primary  endpoint  (i.e., impact  on therapy),  
questionnaires  obtained  pre- and post- 18F-fluciclovine  PET/CT  will be 
compared  to calculate  the fraction  of cases  with a change  in management  
(versus  no change  in planned  management).  The 95% confidence  interval  
will be calculated  using  the Exact  method  for a binomial  distribution.  
Rationale  for Number  of 
Subjects  Assuming  a  prevalence  rate of positive  18F-fluciclovine  PET/CT  of 
approximately  40%,  of which  30% will be expected  to change  the 
physician’s  intended  management  plan and binding  of the 95% CI width  at 
0.20 (i.e., half –length  at 0.10),  89 18F-fluciclovine  positive  patients  will be 
needed  for the assessment  of our primary  aim. After  taking  into account  the 
random  nature  of the observed  numbers  of patients  meeting  the clinical  
criteria  in a prospective  study,  and potential  data loss, provide  a 90% 
probability  of yielding  the required  number  of patients  for the primary  
comparison  it is planned  to enroll at least 292 and up to 330 patients  into the 
study  in order  to obtain  89 evaluable  patients.  
LOCATE  16 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STUDY  SCHEMA  
Optional
biopsy  of 
positive  (+) 
18F- 
sites (as 
clinically  
indicated)  
Adult  Males  
Suspicion  of
recurrent  prostate
carcinoma  after
presumed
definitive  therapy
for 
disease  (adapted
from  AUA  2013  and
NCCN  1.2016):  
 
Post - 
prostatectomy:
Detectable  PSA
to ≥0.2  ng/ml  
(confirmed)  
Radiotherapy:
PSA rise by ≥ 2.0 
ng/ml  over  
nadir. 
 
18F-fluciclovine  
 
Imaging  
Questionnaire  on 
planned  treatment  
PRE-18F- 
FLUCICLOVINE  
PET/CT  
Questionnaire  on 
planned  treatment  
POST -18F 
FLUCICLOVINE  
PET/CT   
 
 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
6-month Follow -up SCREENING/REGISTRATION  
LOCATE  17 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
1 BACKGROUND  
 
Biochemically  recurrent  prostate cancer  is a common  clinical  problem.  Optimal  strategies  for detection  of 
persistent  or recurrent  disease  and for management  of such patients  are not currently  well defined.  Radical  
therapy  for prostate  cancer  patients  without  pre-treatment  evidence  of distant  disease  using  standard -of- 
care diagnostic  imaging  studies  improves  disease -specific  survival  and overall  survival,  (1) but relapse  
remains  a significant  problem.  Biochemical  failure  rates despite  optimal  therapy  can be as high as 30% 
with intermediate -risk disease  (2) and 50%  with high-risk disease.  (3) Some  of these  relapses  are 
attributable  to distant  metastases  not detected  by standard  imaging  modalities.  Others  are attributable  to 
locally  persistent  disease  in the region  of the prostate  or proximate  nodes.  Management  of recurrent  
disease  after curative -intent  local  therapy  optimally  requires  disease  localization.  
Standard -of-care staging  imaging  for prostate  cancer  as recommended  by the current  National  
Comprehensive  Cancer  Network  guidelines  includes  99mTc-MDP  bone  scintigraphy  and pelvic  imaging  
with CT or MRI.  (4) In the setting  of early  biochemical  relapse  after prostatectomy,  although  used to help 
define  the extent  of disease,  these  studies  are generally  uninformative.  As a result,  clinicians  must often  
decide  for or against  further  local  therapy  (e.g.,  salvage  external  beam  radiation  therapy  for biochemical  
recurrence  after prostatectomy)  as guided  by nomogram -based  probabilities  rather  than anatomic  
localization.  A more  sensitive  imaging  modality  that could  offer anatomic  localization  within  the clinical  
setting  of early  PSA relapse  would  better  inform  treatment  decisions  and improve  the management  of 
patients  with apparent  recurrence  based  on PSA levels.  
Prostate  cancer  functional  imaging  with PET is presently  used on a limited  basis.  Widely  available,  PET 
or PET/CT  with 18F-fluorodeoxyglucose  (FDG)  is not standard  as FDG  uptake  is usually  low in prostate  
cancer  prior  to the development  of castration -resistant  disease.  18F-sodium  fluoride  PET is more  sensitive  
than standard  99mTc-MDP  bone  scintigraphy,  but both methods  are non-specific  and do not image  cancer  
outside  of the skeleton.  Acetate - and choline -based  PET tracers  have been the subject  of study  but are not 
broadly  approved  and available.  PET or PET/CT  with the experimental  L-leucine  analog  18F-fluciclovine  
has demonstrated  promise  and is the subject  of this experimental  protocol.  
 
 
1.1 Overview  of Clinical  Studies  
Published  data from  single -institution  studies  of 18F-fluciclovine  PET have preliminarily  demonstrated  its 
operating  characteristics  in over one hundred  study  subjects  with recurrent  prostate  cancer  after curative - 
attempt  primary  therapy  (see Figure)  (5,6,7). Dosimetry  has previously  been  described  and is notable  for a 
favorable  pelvic  imaging  profile  because  of low levels  of uptake  within  the urinary  bladder.  18F- 
fluciclovine  PET/CT  has demonstrated  approximately  90% sensitivity  and 40-67% specificity  for 
detection  of cancer  in the prostate  bed. It has demonstrated  55-100%  sensitivity  and more  than 95% 
specificity  for the detection  of disease  outside  of the prostate  bed. Multi -center  study  is needed  to 
determine  the clinical  impact  of localization  of suspected  prostate  cancer  recurrence  by 18F-fluciclovine  
PET/CT,  specifically  the impact  on patient  management.  
LOCATE  18 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
 
 
The goal of the proposed  study  is to further  evaluate  the impact  of 18F-fluciclovine  PET/CT  of prostate  
cancer  in a multi -institution  study.  We hypothesize  that by identifying  disease  in or outside  of the prostate  
bed—either  in regional  lymph  nodes  or distant  disease  sites,  18F-fluciclovine  PET/CT  will impact  the 
approach  to patient  management.  This typically  involves  prostate  bed irradiation  in patients  with prior 
prostatectomy,  and a combination  of additional  focal  therapy  such as radiotherapy,  cryotherapy,  and/or  
systemic  therapy  in patients  treated  initially  with local  radiotherapy  or brachytherapy.  We propose  a study  
of men who have  undergone definitive  treatment  of localized  prostate  cancer  (e.g. by prostatectomy,  local  
radiotherapy,  brachytherapy)  and are presenting  with rising  PSA levels  indicative  of recurrent  or persistent  
disease.  We have  chosen  to study patients  without  evidence  o f  disease  (or with equivocal  findings)  
by standard  imaging  (bone  scintigraphy  and CT or MRI)  and with PSA levels  in the range  where  
imaging  findings  outside  the prostatic  bed would  be expected  to have a significant  impact  on treatment.  
Study  participants  with negative  or equivocal  conventional  staging  studies  (99mTc-MDP  bone  scintigraphy  
/NaF PET -CT (dependent on standard of care at the institution) and abdominal -pelvic  CT or MRI)  will undergo  
18F-fluciclovine  PET/CT.  
 
 
2 STUDY  RATIONALE  
 
This study  has the potential  to improve  management  of a common  disease  state (biochemically  recurrent  
prostate  cancer)  within  the most  common  cancer  among  men.  If successful,  it will establish  an imaging  
strategy  that is demonstrated  to appropriately  modify  care compared  to current  standard  imaging  
approaches.  Single  center  experience  of a similar  study  was reported  at the SNMMI  meeting  in 2015  (11). 
They  reported  initial  findings  from  an ongoing  randomized  study  in which  24/54  patients  with rising  PSA 
and negative  pelvic  MRI and 99mTc-MDP  bone  scan were  randomized  to receive  18F-fluciclovine  PET/CT  
before  definitive  treatment.  In these patients  6/23 had changes  made  to their radiation  fields  as a result  of 
the PET/CT;  1 had the offer  of radiotherapy  withdrawn.  Overall  in these  early  results  7/24 patients  
(29.2%)  had the radiotherapy  decision  modified  by the results  of the PET/CT  scan.  If these  results  can be 
confirmed  in a multi -center  study  there is the potential  to improve  medical  care and  quality  of life among  
men with prostate  cancer  in several  ways.  First,  identification  of disease  in the prostate  bed and/or  
regional  nodes  would  provide  evidence  in support  of salvage  radiation  treatment,  and help to plan 
radiotherapy.  In addition,  the absence  of distant  disease  by 18F-fluciclovine  PET/CT  in patients  with a 
PSA ≥ 1 ng/mL  would  preserve  salvage  local  therapy  as a clinical  option  beyond  the time typically  
offered.  Second,  identification  of distant  disease  at the time of consideration  of salvage  radiation  therapy  
would  allow  patients  to forego  radiation  that would  ultimately  be futile.  This would  spare  those  patients  

LOCATE  19 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
radiation -induced  side effects  such as impaired  recovery  of continence,  impaired  recovery  of erectile  
function,  and diarrhea.  Finally,  the absence  of disease  detection  using  a sensitive  imaging  modality  in 
patients  with a rising  PSA would  have the potential  to delay  initiation  of systemic  androgen  deprivation  
therapy,  a treatment  strategy  that causes  a number  of morbid  side effects  that are detrimental  to quality  of 
life. 
This prospective  study  will enroll  up to 330 men with PSA-persistent  or PSA-recurrent  prostate  cancer  
after curative -intent  primary  therapy  and negative  or equivocal  findings  on standard -of-care imaging  (see 
enrolment  criteria  for details  of eligibility).  Consenting  participants  will be imaged  with 18F-fluciclovine  
PET/CT.  Site clinicians  will manage  study  subjects  per standard  practices  and will document  any change  
in treatment  based  on review  of 18F-fluciclovine  PET/CT  findings.  Rates  of disease  detection  
(radiographic -only,  and pathologically  confirmed)  will be described.  
 
 
2.1 Risk -Benefit  Assessment  
Benefits  
The research  scans  may provide  further  clinical information  regarding  the patient’s  disease  status  that 
may not have  been  appreciated  using  other  standard  of care tests.  If such information  arises,  this will be 
reported  back to the responsible  clinician  to help direct  the patient’s  further  management.  This may 
provide  a direct  benefit  to the subject.  
Risks  
The risks from  the imaging  studies  to subjects  mainly  relate  to the intravenous  injection  and the radiation  
emitted  by the radiopharmaceutical  and CT.  Intravenous  injection  carries  a small risk of infection  and 
hematoma.  
 
The mean  effective dose per unit administered  activity  of 18F-fluciclovine  is 22.1µSv/MBq  (8). An 
administered  activity  of 10mCi  (370 MBq)  will result  in an effective  dose of 8.2mSv.  The maximum  
effective  dose due to the CT transmission  scan will vary from  site to site, but as a guide  a dose of 7 mSv 
would  be expected  (details  of scanner -specific  CT effective  doses  will be given  in the Study  Imaging  
Manual).   The effective  dose due to the CT acquisition  will be in accordance  with ALARA  (As Low As 
Reasonably  Achievable)  principles.  The total dose of 15.2mSv  is in line with other  common  nuclear  
medicine  procedures.  
 
As with all imaging  techniques  there  is the risk that the PET/CT  scan may provide  a false positive  image  
(giving  the appearance  of cancer)  in sites where  it is not present,  due to other  events  in the body  such as 
inflammation  or false negative  (failing  to detect  a nidus  of cancer).  Thus  patients  should  continue  to be 
reviewed  and may require  other  investigations,  including  biopsy,  to confirm  scan findings.  
 
3 STUDY  OBJECTIVES  
3.1 Primary  Objective  
The primary  objective  is to measure  the fraction  of patients  for whom  18F-fluciclovine  PET/CT  alters  
patient  treatment  through  detection  of disease  after curative -intent  treatment  in a population  of men with 
elevated  PSA levels  indicative  of persistent  or recurrent  prostate  cancer  and negative  or equivocal  findings  
on standard -of-care diagnostic  imaging  tests.  
LOCATE  20 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
3.2 Secondary  Objectives  
1. To measure  the fraction  of patients  for whom 18F-fluciclovine  PET/CT  leads  to a change  of actual  
management  by comparison  with the intended  management  plan before  18F-fluciclovine  PET/CT.  
2. To estimate  the fraction  of patients  in whom  18F-fluciclovine  PET/CT  yields  evidence  of recurrent  
disease  on the basis  of imaging  results.  
3. To estimate  1) the rates of detecting  regionally  recurrent  disease  (i.e., prostatic  bed-only and/or  pelvic  
disease  outside  of the bed) and 2) the rate of detecting  distant  metastases  (i.e., bone  metastases,  
visceral  metastases,  or non-regional  nodal  metastases)  with 18F-fluciclovine  PET/CT  in the study  
population.  
4. To determine  1) the PPV of 18F-fluciclovine  PET/CT  to detect  regionally  recurrent  disease  and 2) the 
PPV of 18F-fluciclovine  PET/CT  to detect  distant  metastases  in the study  population  in patients  who 
undergo  optional  biopsy  of 18F-fluciclovine  PET/CT  findings  or have documentation  of disease  status  
based  on other  imaging  and/or  follow -up data. For soft tissue  disease  these  calculations  will be 
limited  to those  patients  who undergo  a confirmatory  biopsy  and for bone  disease  those with 
confirmatory  findings  on MRI any time during  the 6-month  follow  up. The denominator  for the 
analysis  will be [lesions  biopsied  + bone  lesions].  
5. To explore  differences  in estimated  cost of treatment  plans  determined  prior  to and following  18F- 
fluciclovine  PET/CT.  
 
4 STUDY  DESIGN  
 
4.1 Study  Overview  
This prospective  study  will enroll  up to 330 men with PSA-persistent  or PSA-recurrent  prostate  cancer  
after curative -intent  primary  therapy  and negative  or equivocal  findings  on standard -of-care imaging  (see 
enrolment  criteria  for details  of eligibility).  Consenting  participants  will be imaged  with 18F-fluciclovine  
PET/CT.  Site clinicians  will manage  study  subjects  per standard  practices  and will document  any change  
in treatment  based  on review  of 18F-fluciclovine  PET/CT  findings.  Additionally,  as clinically  indicated,  
optional  biopsy  will be performed.  All participants  will be followed  for up to 6 months,  with clinical  data 
collected  for this study:  PSA measurement  from  scan for 6 months.  An expert  reader  will provide  
guidance  to local  readers  on request.  The final reporting  of the PET/CT  scan will be a single  report  by the 
local  reader  following  any such discussion.  
 
 
5 CRITERIA  FOR  EVALUATION  
 
5.1 Primary  Efficacy  Endpoint  
For the primary  objective,  the change  of management  will be based  on referring  physician  questionnaires  
completed  pre- and post- 18F-fluciclovine  PET/CT  (Intended  v Revised   Management   Plans).  Management  
options  on referral  will include  prostatic  bed radiotherapy  (±hormone treatment ), prostatic  bed plus 
regional  radiotherapy,  cryoablation,  surgery.  Post PET/CT  scan additional  options  include,  inter alia no 
therapy,  treatment  of oligometastatic  disease,  hormonal and other  systemic  therapies).  
 
5.2 Secondary  Efficacy  Endpoints  
1. Per-patient  impact  (yes/no)  of 18F-fluciclovine  PET/CT  on pre-PET intended  versus  post-PET actual  
patient  management  (assessed  at 6 months  post scan)  
LOCATE  21 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
2. The rate of detection  of any disease  site by 18F-fluciclovine  PET/CT  in the study  population;  
3. The rate of detection  of 1) prostatic  bed and other  pelvic disease  and 2) distant  metastases  (i.e., bone  
metastases,  visceral metastases,  or non-regional  nodal  metastases)  with 18F-fluciclovine  PET/CT  in 
the study  population;  
4. The PPV of 18F-fluciclovine  PET/CT  to detect  regionally  recurrent  disease  compared  to biopsy  in 
those  patients  who undergo  a regional  disease  biopsy  on the basis  of a 18F-fluciclovine  PET/CT  
finding  or in case of bony  disease  a correlation  with MRI or biopsy.  
5. The PPV of 18F-fluciclovine  PET/CT  to detect  distant  disease  compared  to biopsy  in those  patients  
who undergo  a distant  disease  biopsy  on the basis  of a 18F-fluciclovine  PET/CT  finding  or in case of 
bony  disease  a correlation  with MRI or biopsy.  
 
5.3 Safety  Evaluations  
1. Change  from  baseline  QTc intervals  and any clinically  significant  alterations  in EKG  after 18F- 
fluciclovine  PET/CT  scanning  
2. Change  from  baseline  values  in hematology  and biochemistry  profiles  after 18F-fluciclovine  PET/CT  
scanning  
3. Incidence  of adverse  events  occurring  after the 18F-fluciclovine  injection  
 
 
6 SUBJECT  SELECTION  
 
6.1 Study  Population  
Eligible  patients  that  meet  inclusion  and exclusion  criteria   will have suspicion  of recurrent  prostate  
carcinoma  after presumed  definitive  therapy  for primary  disease.  
 
6.2 Inclusion  Criteria  
1. History  of histologically  confirmed  adenocarcinoma  of the prostate  post curative -intent  local  
treatment  (radical  prostatectomy,  local  radiotherapy,  brachytherapy)  
2. Suspicion  of recurrent  prostate  carcinoma  after presumed  definitive  thera py for primary  
disease,  defined  as 
a. Post-prostatectomy  (with/without  adjuvant  RT):  Detectable  or rising  PSA level  that is 
>0.2 ng/mL  with a second  confirmatory  level  of   >0.2 ng/mL  
b. Post radiotherapy  (without  RP): PSA rise ≥2ng/mL  over nadir  
3. Negative  or equivocal  findings  on standard -of-care imaging  for restaging  of disease  in the 
previous  60 days consisting  of: 
a. Whole -body  99mTc-MDP bone  scintigraphy   or NaF PET -CT (dependent on standard of care 
at the institution) and 
b. Either  CT or MRI of the pelvis  (or the abdomen  and pelvis).  
4. Being  considered  for salvage  therapy  
5. Previous  cryotherapy,  external beam  radiation,  or HiFU  must  have occurred  at least one year in 
the past. 
6. Previous  brachytherapy  treatment  will have  occurred  at least 2 years  in the past 
LOCATE  22 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
7. Ability  to understand  and the willingness  to sign a written  informed  consent  
 
6.3 Exclusion  Criteria  
1. Ongoing  treatment  with any systemic  therapy  intended  for the treatment  of prostate  cancer  (e.g.,  
antiandrogen  or LHRH  agonist  or antagonist)  
2. Androgen  deprivation  therapy  (ADT)  in the past 3 months.  
3. History  of bilateral  orchiectomy.  
4. Inability  to tolerate  18F-fluciclovine  PET/CT.  
 
7 CONCURRENT  MEDICATIONS  
 
7.1 Allowed Medications  and Treatments  
All standard  and approved  treatments  are permitted  except  for those  specifically  prohibited  in section  7.2. 
 
7.2 Prohibited  Medications  and Treatments  
The following  medications  and treatments  are prohibited  prior  to the 18F-fluciclovine  PET/CT. Any 
administration  of 18F-fluciclovine  during  treatment  with these  will be considered  a protocol violation.  
 Treatment  with any systemic  therapy  intended  for the treatment  of prostate  cancer  (e.g.,  
antiandrogen  or LHRH  agonist  or antagonist)  
 Bilateral orchiectomy  
 
8 STUDY  TREATMENTS  
 
8.1 Formulation of Test Product  
18F-fluciclovine is a radiolabelled  synthetic  amino  acid.  The radioactive  isotope 18F decays  with a half-life 
of approximately  110 minutes.  
 
 
Chemical  formula  
 18 C5H8 FNO 2 
 
 
 
 
 
 
Chemical  structure   
 
H NH2 
 
 
18F COOH  
 
Chemical  name  
LOCATE  23 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
(anti) -1-amino -3-[18F]fluorocyclobutane -1-carboxylic  acid.  
 
 
Physiological  effects  
Biodistribution  and radiation  dosimetry  studies  have demonstrated  physiological  uptake  of 18F- 
fluciclovine  to be highest  in the liver and pancreas,  with rapid  biological  clearance.  (9) There is low albeit  
prolonged  uptake  in skeletal  muscle  and bone  marrow,  with clearance  dominated  by the tracer  half-life. 
(9) 
 
8.2 Packaging  and Labeling  
The investigational  agent  is supplied  as a unit dose for injection  in a syringe  with a radioactive  
concentration  at a reference  date and time that is stated  on the container  label.   Each  syringe  is supplied  in 
a container  providing  appropriate  radiation  shielding.  Information  will be provided  with the shipment  
giving  the confirmation  number,  radioactive  concentration  of injection  (mCi/mL)  at a stated  time and 
date, shelf  life information,  protocol  number  and a unique prescription  number.  The radiochemical  purity  
of 18F-fluciclovine  injection  is not less than 95% during  the shelf  life of the product  
 
8.3 Supply  of Study  Drug  at the Site 
Sites  will be provided  with instructions  for ordering  the 18F-fluciclovine  injections  for use in the study.  
The order  for a specific  patient  to be scanned  at a specific  date and time must  be made  to PETNET  
Solutions  Centralized  Scheduling  Team  (Tel:  1 877 473 8638).  The 18F-fluciclovine  will be delivered  
from  the radiopharmacy  to the imaging  site by courier.  Each  syringe  is supplied  in a container  providing  
appropriate  radiation  shielding.  The site must  keep records  of all shipments  of 18F-fluciclovine  received,  
dispensing  and disposal/destruction  performed  on site as is appropriate  to each facility.  
 
8.4 Dispensing  
When  the study  site receives  the dose and prior  to administration,  the activity  in the syringe  will be 
measured  in a dose calibrator.  Should  the activity  be less than 8mCi  or the volume  required  exceed  5 mL 
undiluted  material  or the administration  be more  than 10 hours  from  manufacture  the scan should  not be 
performed.  
 
8.5 Administration  Instructions  
Prior  to PET/CT,  10mCi  ±20%  of 18F-fluciclovine  will be administered  as an IV bolus injection 
followed  by a 10 mL saline  flush.  18F-fluciclovine  will be injected  through  a cannula  (or indwelling  
catheter)  with the subject  lying  in a supine  position  and in an antecubital  vein or another  vein that will 
provide  access.  The administration  site will be evaluated  pre- and post- administration  for any reaction 
(e.g. bleeding,  hematoma,  redness,  or infection).  Documentation  of administration  to a subject  will be 
recorded  according  to standard  of care and on the appropriate  eCRF,  including  date,  prescription  number,  
total volume,  start/stop  time of administration,  and injection  site. 
 
8.6 Study  Drug  Accountability  
An accurate  and current  accounting  of the dispensing  and disposal  of 18F-fluciclovine  for each subject  
will be recorded  on the Investigational  Drug  Accountability  Record.  The study  monitor  will verify  this 
document  throughout  the course  of the study.  
LOCATE  24 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
9 STUDY  PROCEDURES AND  GUIDELINES  
 
A Schedule  of Events  representing  the required  testing  procedures  to be performed  for the duration  of the 
study  is diagrammed  in Appendix  1. 
Prior  to conducting  any study -related  activities,  written  informed  consent  and the Health  Insurance  
Portability  and Accountability  Act (HIPAA)  authorization  must  be signed  and dated  by the subject.  
 
9.1 Informed  Consent  
The participant  must  sign and date the local  site IRB-approved  version  of the Informed  Consent  form  
before  any study -specific  procedures  are performed.  
Written  and oral versions  of the Participant  Information  and Informed  Consent  will be presented  to the 
participants  detailing  no less than:  the exact  nature  of the study;  what  it will involve  for the participant;  
the implications  and constraints  of the protocol;  the known  side effects  and any risks involved  in taking  
part. It will be clearly  stated  that the participant  is free to withdraw  from  the study  at any time for any 
reason  without  prejudice  to future  care,  and with no obligation  to give the reason  for withdrawal.  
The participant  will be allowed  as much  time as wished  to consider  the information,  and the opportunity  
to question  the Investigator,  his referring  physician  or other  independent  parties  to decide  whether  he will 
participate  in the study.  Written  Informed  Consent  will then be obtained  by means  of the participant’s  
dated  signature  and the dated  signature  of the person  who presented  and obtained  the Informed  Consent.  
The person  who obtained  the consent  must  be suitably  qualified  and experienced,  trained  in GCP  and 
informed  consent  procedures.  A copy  of the signed  Informed  Consent  will be given  to the participant.  The 
original  signed  form  will be retained  at the study  site. 
 
 
9.2 Clinical  Assessments  
Data from  the following  assessments  and procedures  should  be documented  in the Subject’s  medical  
records  and recorded  in the eCRF  
1. Concomitant  Medications  
All concomitant  medication  and concurrent  therapies  will be documented  at Screening  and at all 
Visits  and at End of Follow  up. Dose,  route,  unit frequency  of administration,  and indication  for 
administration  and dates  of medication  will be captured.  
2. Demographics  
Demographic  information  will include  age, gender,  race and ethnicity.  
3. Medical  History  
Include  history  of prostate  cancer  and prostate  cancer  treatments,  and other  clinically  significant  
diagnoses.  Prostate  cancer  history  should  include  the date of initial  diagnosis,  initial tumor  stage  and 
Gleason  score,  dates  of definitive  therapy  and adjuvant  treatment  (if given),  and date of diagnosis  of 
biochemical  recurrence.  
4. Imaging  Studies  
Imaging  data will include  all imaging  results  (including  relevant  bone  scans,  CT etc) from  60 days 
before  screening  so the final follow -up and all prostate  cancer  imaging  results  available  from  the 
Subject’s  file 
LOCATE  25 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
5. Vital  Signs  
Blood  pressure  and pulse  rate will be performed  after resting  for 5 minutes.  
6. 12 lead Electrocardiogram  (EKG)  
EKG  will be recorded  as indicated  in Section  10. Original EKGs  are to be anonymized  and forwarded  
to Clinical  Research,  Blue Earth  Diagnostics,  Magdalen  Centre,  Oxford  Science  Park,  Oxford  OX4  
4GA,  United  Kingdom  and copies  maintained  in the Subject’s  medical  record.  
7. PSA Levels  
PSA levels  will be recorded  from  the Subjects  medical  records  
8. Management  Plan  
The Intended  Management  Plan. The treating  physician  will complete  the Management  Plan 
Questionnaire  to document  his/her  intended  treatment  including  planned  radiation  fields,  intended  
resection  limits  of surgery,  use of brachytherapy,  cryotherapy  or HiFU,  intended  use of adjuvant  
therapy.  
The Revised  Management  Plan. Where  an additional  diagnostic  procedure  (e.g.,  imaging  or biopsy)  is 
performed  in light of the PET/CT  findings,  the results  of these  should  be considered  prior  to recording  
the revised  management  plan.  Any such diagnostic  procedures  do not qualify  as a “change”  to clinical  
management.  The treating  physician  will complete  the Management  Plan Questionnaire  to document  
changes  to the Pre-scan Management  Plan.  Changes  include  such responses  as change  to radiation  or 
surgical  fields.  The patient  may enter  another  clinical  trial as part of the Revised  Management  Plan.  
Actual  Management  Plan. At the final follow  up visit any deviations  or changes  to the Revised  
Management  Plan will be documented  
9. Biopsy  
Biopsy  is not required  by the protocol;  however  patients  with PET/CT  positive  findings  in soft-tissue  
supported  by anatomical  abnormalities  on CT or MRI may have  a biopsy  performed  per standard  
practice  where  the procedure  is deemed  clinically  feasible  and safe. Biopsies  completed  within  4 
months  after imaging  will contribute  to the aim of the study.  
1. Biopsy  results  of suspected  bone metastases  conducted  per standard  practice  will also be 
collected.  Bone  lesions  may be followed  up through  imaging  where  biopsy  is not practical.  
2. Based  on local -radiologist/nuclear  medicine  physicians  assessment  of 18F-fluciclovine  PET/CT - 
positive  findings  supported  by anatomic  abnormalities,  conduct  imaging -guided  biopsy  of soft- 
tissue  18F-fluciclovine  -enhancement  region  per institutional  standard  of care;  
3. Submit  pathology  report(s)  to the ACR  Core  Laboratory.  The address  is given  in the Imaging  
Manual.  
10. Blood Chemistry  Profile  
Blood  will be obtained  and sent to each site’s  clinical  chemistry  lab for determination  of serum  
sodium,  potassium,  calcium,  chloride,  BUN,  creatinine,  glutamic  oxaloacetic  transaminase  
(SGOT/AST),  glutamic -pyruvic  transaminase  (SGPT/ALT),  alkaline  phosphatase,  creatine  kinase  
(CK),  lactate  dehydrogenase  (LDH),  albumin,  total protein,  total bilirubin.  
11. Hematology  
Blood  will be obtained  and sent to each site’s  clinical  hematology  lab for a complete  blood  count  
(hemoglobin,  hematocrit,  red blood  cell count,  white  blood  cell count,  white  blood  cell differential,  
and platelet  count  determinations).  
LOCATE  26 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
12. Urinalysis  
Prior  to the 18F-fluciclovine  dosing  a midstream  sample  of urine  will be obtained  and tested  by 
dipstick  for leukocytes,  nitrite,  pH, protein,  ketones,  glucose,  bilirubin,  urobilinogen,  and blood.  This 
will not be repeated  following  scanning  unless  clinically  indicated.  
13. Adverse  Events  
See Section  12. 
 
10 EVALUATIONS BY VISIT  
 
A Schedule  of Events  representing  the required  testing  procedures  to be performed  for the duration  of the 
study  is given  in Appendix  1 
 
10.1 Visit  1 - Screening  
1. Review  the study  with the subject  and obtain  written  informed  consent  and HIPAA  authorization  
2. Record  demographics  data and current  medication  being  taken.  
3. Obtain  medical  history  including  treatment  history.  
4. Confirm  negative  or equivocal  findings  on baseline  imaging  studies  (note:  baseline  imaging  
studies  must  be within  60 days prior  Visit  1). 
5. Measure  vital signs  
6. Obtain  blood  sample  for: 
o PSA testing  
o Hematology  
o Biochemistry  evaluations  
7. Obtain  12-lead EKG  
8. Obtain urine sample for dipstick urinalysis  (may be collected and tested at any time between 
screening and the scan date)  
 
10.2 Enrollment  and PET/CT  Preparation  
Subjects  who have  provided  informed  consent  and who meet  all eligibility  criteria  will be enrolled  into 
the study.   At the time the Subject  is determined  to be eligible,  the following  activities  will be performed:  
1. Register  the Subject  via eCRF  
2. Schedule  the 18F-fluciclovine  PET/CT  imaging  study  within  30 days of Visit  1 
3. The treating  physician  must complete  the Management  Plan Questionnaire.  A copy  of the 
Questionnaire  must  be maintained  in the Subject’s  medical record.  
4. PET/CT  Preparation:  
Subjects  will be required  to fast for at least 4 hours  prior  to the scan,  drinking  only sips of water  
within  4 hours  of the scan if needed  for administration  of medications  and not exercise  from  the 
day before  the scan through  to the time of the scan.  Optionally,  if it is the standard  practice  at the 
site, one hour prior  to scanning,  the patient  may drink  500 mL of oral contrast  (e.g. 1.2%, Readi - 
Cat) over 1 hour to maximize  conspicuity  of abdomen  and pelvic  structures.  No IV CT contrast  
will be used.  
LOCATE  27 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
10.3 Visit 2 – 18F-fluciclovine  PET -CT 
Prior  to the dose of 18F-fluciclovine  and the PET/CT  scan,  the following  assessments  will be performed:  
1. Review  and update  the Subject’s  medical  history  to check  for new health -related  events  and 
changes  to concomitant  medications  since  the Screening  visit.  
2. Ensure  treatment  plan has been documented  prior  to 18F-fluciclovine  PET/CT;  
3. Obtain  vital signs.  
4. Obtain  blood  sample  for:  ) 
o Hematology   ) 
Biochemistry   )  Unless  obtained  at screening  
5. 12-lead EKG   ) 
6. Obtain  a urine  sample  and perform  dipstick  analysis.  ) 
o If the results  are abnormal  these  are to be recorded  and the Subject  is to proceed  to having  the 
fluciclovine  PET/CT  
Dosing  and PET/CT  Procedure : A venous  cannula  will be inserted  and the Subject  will receive one  
dose of 18F-fluciclovine.  Subjects  will be imaged  starting  4 minutes  after injection  from  proximal - 
thigh  to skull  base.  The duration  of the scan is approximately  25 minutes  on the PET/CT  scanner.  
Following  the scan, Subjects  will be encouraged  to drink  water  to encourage  hydration  and frequent  
voiding  to reduce  radiation  dose from  18F-fluciclovine  excretion.  The following  assessments  will be 
performed  
1. Obtain  blood  sample  for: ) 
a. Hematology  ) 
b. Biochemistry  )  Unless  to be obtained  in the next 7 days 
2. 12-lead EKG  ) 
3. Obtain  vital signs  immediately post  scan and at  60 (± 5) minutes,  and 120 (±5) minutes  post-
injection.  
4. Assess  the Subject  for adverse  events  at 30 minutes,  60 minutes,  and 120 minutes  post-injection.  
10.4 Visit  3 - Telephone Consultation  at 24 - 72 ( +/- 4) hours after  dosing  
An  adverse   event   evaluation   will  be  performed   at  24 - 72  hours   (+  4  hours)   after  18F-
fluciclovine  administration  via telephone  consultation.  
 
10.5 Documentation  of Management  plan revision  post 18F-fluciclovine  PET/CT  Scan  (2- 
22 days  following  the scan)  
The treating  physician  will complete  the Management  Plan Questionnaire  to document  changes  to the 
Pre-Scan  Management  Plan.  A copy  of the Questionnaire  must  be maintained  in the Subject’s  medical  
record.  
LOCATE  28 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
10.6 End of Study  (26+/ -4 weeks  post scan)  
The  treating  physician   will  complete   the  Management   Plan  Questionnaire   to  document   the  actual  
treatment  given,  including  any changes  to radiation,  surgery,  or medications  given.  
The following  data from  Visit  2 through  to 6 months  after the 18F-fluciclovine  PET/CT  will be abstracted  
from  the Subject’s  medical record:  
1. All PSA results.  
2. All biopsy  results  and reports.  
3. Restaging  procedure  results  (e.g. bone  scan or CT/MRI  scans).  
4. Current  prostate  cancer  status  and date of recurrence  if applicable.  
5. Adverse  events  reported  by the patient   
6. Date  and cause of death  if applicable.  
 
10.7 Off Study  Criteria  
Subjects  will not  continue  with the study  based  on the following  criteria:  
 Subject  withdraws  consent.  
 Subject  does not complete  18F-fluciclovine  PET/CT  imaging  
 
10.8 Discontinuation/Withdrawal  of Subjects  
Each  Subject  has the right to withdraw  from  the study  at any time without  giving  a reason  and without  
prejudice.  In addition,  a Subject  may be discontinued  from  the study  at any time for any of the following  
reasons:  
 Ineligibility  (recognized/arising  after registration  and prior  to 18F-fluciclovine  administration)  
 Significant  protocol  deviation  
 Significant  non-compliance  with study  requirements  
 Withdrawal  of consent  
 Loss to follow  up 
 Investigator  discretion  
Withdrawal  from  the study  will not result  in exclusion  of the data for that Subject  from  analysis  provided  
all baseline  study  measures  have  been  completed.  
The reason  for withdrawal,  if known,  will be recorded  in the eCRF.  
 
10.9 Replacement of Subjects  
Subjects  who withdraw  from  the study  treatment  will not be replaced  
LOCATE  29 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
11 IMAGING  PROTOCOL  
 
11.1 PET/CT Scanner  
A dedicated  hybrid  PET/CT  scanner  is mandatory.  The selected  PET/CT  scanner  must  be qualified  by the 
study  management  team  and be capable  of performing  both emission  and CT transmission  images  in 
order  to allow  for attenuation -corrected  PET/CT  images.  The ability  to calculate  SUVs  is also mandatory.  
PET/MR  scanners  are not approved  for use on this study.  
 
11.2 18F-fluciclovine  injection  administration  
A venous  cannula  will be inserted,  preferably  in the right arm, and the participant  will receive  10 mCi 
±20%  18F-fluciclovine  injection  diluted  up to 10mL  injected  via the cannula  with arms  down,  as an IV 
bolus injection  followed  by 10mL  flush  with normal  saline  solution.  The participant  will then be 
positioned  supine  in the scanner,  with the arms  above  the head (if possible),  and will be scanned  in the 
direction  of proximal -thigh  to skull  base.  The time from  end of injection  of 18F-fluciclovine  injection  to 
the start of imaging  should  be 3 to 5 minutes  with a goal of 4 minutes.  
 
11.3 18F-fluciclovine  PET/CT  acquisition  
For the PET acquisition,  participants  will be imaged  for approximately  25 minutes.  For the CT acquisition,  
an unenhanced  (no IV contrast)  CT will be employed.  Further  details  on the PET/CT  acquisition  are given  
in the Study  Imaging  Manual.  
 
11.4 Image  Transfer  
Following  the completion  of PET/CT  imaging  at the study  site, the scan data will be sent to the ACR  
Imaging  Core  Laboratory  using  either  the ACR  TRIAD  software,  by uploading  anonymized  files via an 
sFTP  server,  or on physical  media  by courier.  Full details  are in the Study  Imaging  Manual.  
 
11.5 18F-fluciclovine  image  analysis  
Image  interpretation  will be based  on guidelines  derived  from  an international  18F-fluciclovine  Reader  
Consensus  Meeting  held in June 2014  (10).  All readers  will undergo  training  in interpretation  of 18F- 
fluciclovine  PET/CT  scans,  and will have a training  set available  for reference.  
Primary  evaluation  and reporting  of the PET/CT  scan will be site-based  (as per standard  of care).  Support  
for the local  reader  can be provided  on request  by contacting  the Study  Chair  or Co-Chairs  as listed  in the 
protocol.  The report  provided  to the treating  physician  and recorded  in the eCRF  will be that of the Site 
Investigator.  The revised  treatment  decision  will be made  on the report  of the Nuclear  Medicine  physician.  
 
 
12 ADVERSE  EVENT  REPORTING AND  DOCUMENTATION  
 
12.1 Adverse  Events  
An adverse  event  (AE)  is any untoward  medical  occurrence  in a clinical  investigation  of a patient  
administered  a pharmaceutical  product  and that does not necessarily  have a causal  relationship  with the 
treatment.  An AE is therefore  any unfavorable  and unintended  sign (including  an abnormal  laboratory  
finding),  symptom  or disease temporally  associated  with the administration  of an investigational  product,  
whether  or not related  to that investigational  product.   An unexpected  AE is one of a type not identified  in 
LOCATE  30 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
nature,  severity,  or frequency  in the current  Investigator’s  Brochure  or of greater  severity  or frequency  
than expected  based  on the information  in the Investigator’s  Brochure.  
The Investigator  will probe,  via discussion  with the subject,  for the occurrence  of AEs during  each subject  
visit and record  the information  in the site’s  source  documents.  Adverse  events  will be recorded  in the 
patient  eCRF.  Adverse  events  will be described  by duration  (start  and stop dates  and times),  severity,  
outcome,  treatment  and relation  to study  drug,  or if unrelated,  the cause.  
AE Severity  
The National  Cancer  Institute’s  Common  Terminology  Criteria  for Adverse  Events  (CTCAE)  Version  
4.3 (June  14, 2010)  will be used to assess  and grade  event  severity,  including  laboratory  abnormalities  
judged  to be clinically  significant.  The severity  grading  is provided  below  (Table  1). 
Table 1.  CTCAE  (V4.03)  AE Severity  Grading  
 
Severity  (Toxicity  Grade)  Description  
Grade  1 Mild;    asymptomatic    or   mild   symptoms;    clinical   or   diagnostic  
observations  only;  intervention  not indicated.  
Grade  2 Moderate;   minimal,   local  or  non-invasive   intervention   indicated;  
limiting  age-appropriate  daily  activities.  * 
Grade  3 Severe  or medically  significant  but not immediately  life-threatening;  
hospitalization  or prolongation  of hospitalization  indicated;  disabling;  
limiting  self-care. ** 
Grade  4 Life-threatening  consequences;  urgent  intervention  indicated.  
Grade  5 Death  related  to AE 
*Daily  activities  refer to preparing  meals,  shopping  for groceries  or clothes,  using  the telephone,  managing  
money,  etc. 
** Self-care refers  to bathing,  dressing  and undressing,  feeding  self, using  the toilet,  taking  medications,  
and not bedridden.  
If the experience  is not covered  in the modified  criteria,  the guidelines  shown  in Table  2 below  will be 
used to grade severity.  It should  be pointed  out that the term “severe”  is a measure  of intensity  and that a 
severe  event  is not necessarily  serious.  
Table  2.  AE Severity  Grading  
 
Severity  (Toxicity  Grade)  Description  
Mild  (1) Transient  or mild discomfort;  no limitation  in activity;  no medical  
intervention  or therapy  required.  The subject  may be aware  of the sign 
or symptom  but tolerates  it reasonably  well. 
Moderate  (2) Mild   to  moderate   limitation   in  activity,   no  or  minimal   medical  
intervention/therapy  required.  
Severe  (3) Marked  limitation  in activity,  medical  intervention/therapy  required,  
hospitalizations  possible.  
Life-threatening  (4) The subject  is at risk of death  due to the adverse  experience  as it 
occurred.  This does not refer to an experience  that hypothetically  might  
have  caused  death  if it were  more  severe.  
LOCATE  31 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
 
Adverse  Event  Relationship  to Study Drug  
The relationship  of an AE to study  drug will be assessed  using  the following  guidelines  in Table  
3. 
Table  3.  AE Relationship  to Study  Drug  
 
Relationship  
to Drug  Comment  
Definitely  Previously  known  toxicity  of agent;  or an event  that follows  a reasonable  temporal  
sequence  from  administration  of the drug;  that follows  a known  or expected  response  
pattern  to the suspected  drug;  that is confirmed  by stopping  or reducing  the dosage  of 
the drug;  and that is not explained  by any other  reasonable  hypothesis.  
Probably  An event  that follows  a reasonable  temporal  sequence  from  administration  of the 
drug;  that follows  a known  or expected  response  pattern  to the suspected  drug;  that is 
confirmed  by stopping  or reducing  the dosage  of the drug;  and that is unlikely  to be 
explained  by the known  characteristics  of the subject’s  clinical  state or by other  
interventions. 
Possibly  An event  that follows  a reasonable  temporal  sequence  from  administration  of the 
drug;  that follows  a known  or expected  response  pattern  to that suspected  drug;  but 
that could  readily  have been  produced  by a number  of other  factors.  
Unrelated  An event  that can be determined  with certainty  to have no relationship  to the study  
drug. 
 
12.2 Serious  Adverse  Event  (SAE)  
An SAE is defined  as any adverse  event  occurring  at any dose that results  in any of the following  
outcomes:  
 death  
 a life-threatening  adverse  experience  
 inpatient  hospitalization  or prolongation  of existing  hospitalization  
 a persistent  or significant  disability/incapacity  
 a congenital  anomaly/birth  defect  
Other  important  medical  events  may also be considered  an SAE when,  based  on appropriate  medical  
judgment,  they jeopardize  the subject  or require  intervention  to prevent  one of the outcomes  listed.  
 
 
Serious  Adverse  Event  Reporting  
Study  sites will document  all SAEs  that occur  (whether  or not related  to study  drug)  on an SAE  Report  
Form.  The collection  period  for all SAEs  will begin  after informed  consent  is obtained  and end after 
procedures  for the final study  visit have  been  completed.  
Death  (5) 
 Death  related  to AE 
LOCATE  32 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
All SAEs  following  18F-fluciclovine  PET/CT  must  be reported  on the SAE  reporting  form  within  24 
hours  of the Site Study  Team  becoming  aware  of the event.  All SAE information  must  be recorded  on an 
SAE form  and faxed,  or scanned  and emailed  to: 
Blue Earth  Diagnostics  
SAE E mail:  Drugsafety@pharsafer.com  
Tel: +44 (0) 1483  212155  
Fax: +44 (0) 1483  212178  
Additional  and further  requested   information  (follow -up  or corrections  to the original  case)   will be 
detailed  on a new SAE Report  Form  and faxed/emailed  to the same  address.  
In accordance  with the standard  operating  procedures  and policies  of the local  Institutional  Review  Board  
(IRB)/Independent  Ethics  Committee  (IEC),  the site investigator  will report  SAEs  to the IRB/IEC.  
12.3 Medical  Monitoring  
Dr Peter  Gardiner  MB ChB,  MRCP,  FFPM  should  be contacted  directly  at these  numbers  to report  
medical  concerns  or questions  regarding  safety . 
Phone: +1 -978-502-9098  
E-mail:  p.gardiner@blueearthdx.com  
 
13 PROTOCOL  VIOLATIONS  
A protocol  violation  occurs  when  the subject,  investigator,  or Sponsor  fails to adhere  to significant  
protocol  requirements  affecting  the inclusion,  exclusion,  subject  safety  and primary  endpoint  criteria.  
Protocol  violations  for this study  include,  but are not limited  to, the following:  
 Failure  to meet inclusion/exclusion  criteria  
 Use of a prohibited  concomitant  medication  
 Use of a camera  which  is not validated  for the study  or using  an imaging  technique  different  to that 
described  in Section  11 
Failure  to comply  with Good  Clinical  Practice  (GCP)  guidelines  will also result  in a protocol  violation.  
The Sponsor  will determine  if a protocol violation  will result  in withdrawal  of a subject.  
When  a protocol  violation  occurs,  it will be discussed  with the investigator  and a Protocol  Violation  Form  
detailing  the violation  will be generated.  This form  will be signed  by a Sponsor  representative  and the 
Investigator.  A copy  of the form  will be filed in the site’s  regulatory  binder  and in the Sponsor’s  files.  
 
 
14 STATISTICAL  METHODS  AND  CONSIDERATIONS  
Prior  to the analysis  of the final study  data,  a detailed  Statistical  Analysis  Plan (SAP)  will be written  
describing  all analyses  that will be performed.  The SAP will contain  any modifications  to the analysis  
plan described  below.  
 
Adverse  event  rates will be coded  by body  system  and MedDra  classification  term.  Adverse  events  will 
be tabulated  and will include  the number  of patients  for whom  the event  occurred,  the rate of occurrence,  
and the severity  and relationship  to study  drug.  
 
14.1 Analysis  of Primary  Endpoint  
For the evaluation  of the primary  endpoint  (i.e., impact  on therapy),  questionnaires  obtained  pre- and 
post-18F-fluciclovine  PET/CT  will be compared  to  calculate  the fraction   of  cases   with a  change  in 
management  (versus  no change  in planned  management).  The 95% confidence  interval  will be calculated  
using  the Exact  method  for a binomial  distribution.  
 
 
LOCATE  33 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
 14.2 Analysis  of Secondary Endpoints  
For the evaluation  of the secondary  endpoint  examining  actual  impact  on therapy,  questionnaires  obtained  
pre-FACBC  will be compared  to treatment  executed  post-18F-fluciclovine  PET/CT  to calculate   the fraction  
of cases  with a change  in management  (versus  no change  in planned  management).  For the estimation  
of detection  rate, the proportion  of the 18F-fluciclovine  -PET/CT  positive  results,  95% confidence  interval  
will be calculated  using  the Exact  method  for a binomial distribution.  
 
For each patient  a comparison  will be made  of the results  of the 18F-fluciclovine  PET/CT  results,  any 
histopathology  results,  results  of any other  imaging  and also for the clinical  response  to treatment(s)  
(standard  of truth)  by an Adjudication  Panel.  The PPV,  NPV,  sensitivity  and specificity  will be calculated,  
where  possible,  at lesion  or regional  or patient  level.  The PPV will be calculated  separately  for patients  
undergoing  optional  biopsy  for (1) regional  disease  and (2) distant  disease.  The 95% confidence  interval  
will be calculated  using  the Exact  method  for a binomial  distribution.  The Adjudication  Panel  will 
follow  the Adjudication  Manual  that will prospectively document  the processes  to be used to determine  
a decision  concerning  the result  of the 18F-fluciclovine  PET/CT  scan vs standard  of truth.  
 
Rates  of disease  detection  (radiographic  only and confirmed  by pathology  or MRI)  will be described  
 
14.3 Interim  Analysis  
When the study recruits the required number of 18F-fluciclovine  -PET/CT   positive patients, accrual will be 
stopped .  A corresponding interim analysis for the primary aim will be planned a nd the study results will be 
submitted for potential public presentation prior to completion of all data collection and analyses.   As 
subject recruitment will have been  completed and the trial design will not be modified as a result of this 
interim anal ysis, no adjustment to the type I error is required . 
 
14.4 Sample Size and Randomization  
The primary  objective  of this study  is to measure  the fraction  of patients  for whom  18F-fluciclovine  - 
PET/CT  alters  intended  management  plan.  The sample  size consideration  will be primarily  based  on 
binding  the width  of its 95% confidence  interval,  i.e., precision  analysis.  The prevalence  rate of positive  
18F-fluciclovine  -PET/CT  findings  in this population  is assumed  to be approximately  40%.  About  30% of 
positive  scans  will be expected  to change  the physician’s  intended  management  plan.  (11).  The goal is to 
accurately  assess  the fraction  of change  in intended  management  in these  FACBC  positive  patients.  The 
table  below  lists the calculated  sample  sizes  with respect  to binding  different  95% CI widths  at the 
proportion  of 30%.  The Clopper -Pearson  Exact  method  was used in PASS  12 (Hintze,  J. (2013).  PASS  
12. NCSS,  LLC.  Kaysville,  Utah,  USA.  www.ncss.com ). 
 
 
Confidence  Sample  
Size  
Target   
Actual   
Proportion   
Lower   
Upper   
Width if 
Level  (N) Width  Width  (P) Limit  Limit  P = 0.5 
0.950  341 0.100  0.100  0.300  0.252  0.352  0.109  
0.950  89 0.200  0.199  0.300  0.207  0.406  0.216  
0.950  40 0.300  0.300  0.300  0.166  0.465  0.324  
 
If the goal is to bind the 95% CI width  at 0.20 (i.e., half –length  at 0.10),  then 89 FACBC  positive  
patients  will be needed  for the assessment  of our primary  aim. Since  the positivity  rate is assumed  to be 
around  40% in the study  population,  we need to enroll  223 patients.  Due to the random  nature  of the 
observed  numbers  of patients  meeting  the clinical  criteria  in a prospective  study,  a sample  size correction  
technique  attributed  to (12) was applied.  Our calculation  shows  that after adding  25 extra  patients  (i.e., 
248 in total),  we can be 90% sure to yield  the required  numbers  of patients  meeting  the criteria.  After  
taking  15% of potential  data loss into consideration,  we will need 292 patients  in this study.   This number  
LOCATE  34 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
will be 1,059  for binding  the 95% CI width  at 0.10,  and 138 for binding  the 95% CI width  at 0.30.  If the 
bandwidth  of 95% CI remains  at 0.20,  but the prevalence  rate of positive  18F-fluciclovine  scans  is lower  
than 0.40, it is estimated  that we may need to enrol  up to 330 patients  into the study  in order  to obtain  89 
evaluable  patients.  
 
 
 
 
15 DATA  COLLECTION,  RETENTION  AND  MONITORING  
 
15.1 Data  Collection  Instruments  
The Investigator  will prepare  and maintain  adequate  and accurate  source  documents  designed  to record  all 
observations  and other  pertinent  data for each subject  treated  with the study  drug.  
Study  personnel  at each site will enter  data from  source  documents  corresponding  to a subject’s  visit into 
the protocol -specific  electronic  Case  Report  Form  (eCRF)  when  the information  corresponding  to that 
visit is available.  Subjects  will not be identified  by name  in the study  database  or on any study  
documents  to be collected  by the Sponsor  (or designee),  but will be identified  by a site number,  subject  
number  and initials.  
 
If a correction  is required  for an eCRF,  the time and date stamp  tracks  the person  entering  or updating  
eCRF  data and creates  an electronic  audit  trail. The Investigator  is responsible  for all information  collected  
on subjects  enrolled  in this study.  All data collected  during  the course  of this study  must  be reviewed  
and verified  for completeness  and accuracy  by the Investigator.  A copy  of the CRF will be provided  to 
the Investigator’s  site at the completion  of the study.  
 
15.2 Data  Management  Procedures  
The data will be entered  into a validated  database.  The Data  Management  group  will be responsible  for 
data processing,  in accordance  with procedural  documentation.  Database  lock will occur  once quality  
assurance  procedures  have been  completed.  
 
All procedures  for the handling  and analysis  of data will be conducted  using  good  computing  practices  
meeting  FDA  guidelines  for the handling  and analysis  of data for clinical trials.  
 
15.3 Data  Quality Control  and Reporting  
After  data have been  entered  into the study  database,  a system  of computerized  data validation  checks  
will be implemented  and applied  to the database  on a regular  basis.  Queries  are entered,  tracked,  and 
resolved  through  the EDC  system  directly.  The study  database  will be updated  in accordance  with the 
resolved  queries.   All changes  to the study  database  will be documented.  
 
15.4 Archiving of Data  
The database  is safeguarded  against  unauthorized  access  by established  security  procedures;  appropriate  
backup  copies  of the database  and related  software  files will be maintained.  Databases  are backed  up by 
the database  administrator  in conjunction  with any updates  or changes  to the database.  
 
At critical  junctures  of the protocol  (e.g.,  production  of interim  reports  and final reports),  data for analysis  
is locked  and cleaned  per established  procedures.  
LOCATE  35 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
15.5 Availability  and Retention  of Investigational  Records  
The Investigator  must  make  study  data accessible  to the monitor,  other  authorized  representatives  of the 
Sponsor  (or designee),  IRB/IEC,  and Regulatory  Agency  (e.g.,  FDA)  inspectors  upon  request.   A file for 
each subject  must  be maintained  that includes  the signed  Informed  Consent,  HIPAA  Authorization  and 
Assent  Form  and copies  of all source documentation  related  to that subject.   The Investigator  must  ensure  
the reliability  and availability  of source  documents  from  which  the information  on the CRF  was derived.  
All study  documents  (patient  files,  signed  informed  consent  forms,  copies  of CRFs,  Study  File Notebook,  
etc.) must  be kept secured  for a period  of two years  following  marketing  of the investigational  product  or 
for two years  after centers  have been  notified  that the IND has been discontinued.   There  may be other  
circumstances  for which  the Sponsor  is required  to maintain  study  records  and, therefore,  the Sponsor  
should  be contacted  prior  to removing  study  records  for any reason.  
 
15.6 Monitoring  and Auditing  
Monitoring  visits  will be conducted  by representatives  of the Sponsor  according  to the U.S. CFR Title 21 
Parts  50, 56, and 312 and ICH Guidelines  for GCP  (E6).  By signing  this protocol,  the Investigator  
grants  permission  to the Sponsor  (or designee),  and appropriate  regulatory  authorities  to conduct  on-site 
monitoring  and/or  auditing  of all appropriate  study  documentation.  
 
15.7 Subject  Confidentiality  
In order  to maintain  subject  confidentiality,  only a site number,  subject  number  and subject  initials  will 
identify  all study  subjects  on CRFs  and other  documentation  submitted  to the Sponsor.  Additional  
subject  confidentiality  issues  (if applicable)  are covered  in the Clinical  Study  Agreement.  
 
16 ADMINISTRATIVE, ETHICAL, REGULATORY  CONSIDERATIONS  
The study  will be conducted  according  to the Declaration  of Helsinki,  Protection  of Human  Volunteers  
(21 CFR  50), Institutional  Review  Boards  (21 CFR  56), and Obligations  of Clinical  Investigators  (21 
CFR  312).  
 
To maintain  confidentiality,  all laboratory  specimens,  evaluation  forms,  reports  and other  records  will be 
identified  by a coded  number  and initials  only.  All study  records  will be kept in a locked  file cabinet  and 
code sheets  linking  a patient’s  name  to a patient  identification  number  will be stored  separately  in another  
locked  file cabinet.  
 
Clinical  information  will not be released  without  written  permission  of the subject,  except  as necessary  
for monitoring  by the FDA.  The Investigator  must  also comply  with all applicable  privacy  regulations  
(e.g.,  Health  Insurance  Portability  and Accountability  Act of 1996,  EU Data  Protection  Directive  
95/46/EC).  
 
16.1 Protocol  Amendments  
Any amendment  to the  protocol  will be written  by the Sponsor.  Protocol  amendments  cannot  be 
implemented  without  prior  written  IRB/IEC  approval  except  as necessary  to eliminate  immediate  safety  
hazards  to patients.  A protocol  amendment  intended  to eliminate  an apparent  immediate  hazard  to 
patients  may be implemented  immediately,  provided  the IRBs  are notified  within  five working  days.  
 
16.2 Institutional  Review  Boards  and Independent  Ethics  Committees  
The protocol  and consent  form  will be reviewed  and approved  by the IRB/IEC  of each participating  
center  prior  to study  initiation.  Serious  adverse experiences  regardless  of causality  will be reported  to the 
IRB/IEC  in accordance  with the standard  operating  procedures  and policies  of the IRB/IEC,  and the 
Investigator  will keep the IRB/IEC  informed  as to the progress  of the study.  The Investigator  will obtain  
assurance  of IRB/IEC  compliance  with regulations.  
LOCATE  36 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
Any documents  that the IRB/IEC  may need to fulfill  its responsibilities  (such  as protocol,  protocol  
amendments,  Investigator’s  Brochure,  consent  forms,  information  concerning  patient  recruitment,  
payment  or compensation  procedures,  or other  pertinent  information)  will be submitted  to the IRB/IEC.  
The IRB/IECs  written  unconditional  approval  of the study  protocol  and the informed  consent  form  will be 
in the possession  of the Investigator  before  the study  is initiated.  The IRB/IECs  unconditional  approval  
statement  will be transmitted  by the Investigator  to Blue  Earth  Diagnostics  Ltd prior  to the shipment  of 
study  supplies  to the site. This approval  must refer to the study  by exact  protocol  title and number  and 
should  identify  the documents  reviewed  and the date of review.  
 
Protocol  and/or  informed  consent  modifications  or changes  may not be initiated  without  prior  written  
IRB/IEC  approval  except  when  necessary  to eliminate  immediate  hazards  to the patients  or when  the 
change(s)  involves  only logistical  or administrative  aspects  of the study.  Such  modifications  will be 
submitted  to the IRB/IEC  and written  verification  that the modification  was submitted  and subsequently  
approved  should  be obtained.  
 
The IRB/IEC  must  be informed  of revisions  to other  documents  originally  submitted  for review;  serious  
and/or  unexpected  adverse  experiences  occurring  during  the study  in accordance  with the standard  
operating  procedures  and policies  of the IRB;  new information  that may affect  adversely  the safety  of the 
patients  of the conduct  of the study;  an annual  update  and/or  request  for re-approval;  and when  the study  
has been completed.  
 
16.3 Informed  Consent  Form  
Informed  consent  will be obtained  in accordance  with the Declaration  of Helsinki,  ICH GCP,  US Code  of 
Federal  Regulations  for Protection  of Human  Subjects  (21 CFR 50.25[a,b],  CFR 50.27,  and CFR  Part 56, 
Subpart  A), the Health  Insurance  Portability  and Accountability  Act (HIPAA,  if applicable),  and local  
regulations.  
 
The Investigator  will prepare  the informed  consent  form,  assent  and HIPAA  authorization  and provide  the 
documents  to the Sponsor  or designee  for approval  prior  to submission  to the IRB/IEC.  The consent  form  
generated  by the Investigator  must  be acceptable  to the Sponsor  and be approved  by the IRB/IEC.  The 
written  consent  document  will embody  the elements  of informed  consent  as described  in the International  
Conference  on Harmonization  and will also comply  with local  regulations.  The Investigator  will send an 
IRB/IEC -approved  copy  of the Informed  Consent  Form  to the Sponsor  (or designee)  for the study  file. 
A properly  executed,  written,  informed  consent  will be obtained  from  each subject  prior  to entering  the 
subject  into the trial. Information  should  be given  in both oral and written  form  and subjects  must  be 
given  ample  opportunity  to inquire  about  details  of the study.  A copy  of the signed  consent  form  (and 
assent)  will be given  to the subject  or legal  representative  of the subject  and the original  will be 
maintained  with the subject’s  records.  
 
16.4 Publications  
The preparation  and submittal  for publication  of manuscripts  containing  the study  results  shall  be 
in accordance  with a process  determined  by mutual written  agreement  among  the study  Sponsor  
and participating  institutions.  The publication  or presentation  of any study  results  shall  comply  
with all applicable  privacy  laws,  including,  but not limited  to, the Health  Insurance  Portability  
and Accountability  Act of 1996.  
 
16.5 Investigator  Responsibilities  
By signing  the Agreement  of Investigator  form,  the Investigator  agrees  to: 
LOCATE  37 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
1. Conduct  the study  in accordance  with the protocol  and only make  changes  after notifying  the 
Sponsor  (or designee),  except  when  to protect  the safety,  rights  or welfare  of subjects.  
2. Personally  conduct  or supervise  the study  (or investigation).  
3. Ensure  that the requirements  relating  to obtaining  informed  consent  and IRB review  and approval  
meet  federal  guidelines,  as stated  in § 21 CFR,  parts  50 and 56. 
4. Report  to the Sponsor  or designee  any AEs that occur  in the course  of the study,  in accordance  with 
§21 CFR 312.64.  
5. Ensure  that all associates,  colleagues  and employees  assisting  in the conduct  of the study  are 
informed  about  their obligations  in meeting  the above  commitments.  
6. Maintain  adequate  and accurate  records  in accordance  with §21 CFR  312.62  and to make  those  
records  available  for inspection  with the Sponsor  (or designee).  
7. Ensure  that an IRB that complies  with the requirements  of §21 CFR  part 56 will be responsible  for 
initial  and continuing  review  and approval  of the clinical  study.  
8. Promptly  report  to the IRB and the Sponsor  (or designee)  all changes  in the research  activity  and all 
unanticipated  problems  involving  risks to subjects  or others  (to include  amendments  and IND safety  
reports).  
9. Seek  IRB approval  before  any changes  are made  in the research  study,  except  when  necessary  to 
eliminate  hazards  to the patients/subjects.  
10. Comply  with all other  requirements  regarding  the obligations  of clinical  investigators  and all other  
pertinent  requirements  listed  in § 21 CFR part 312. 
LOCATE  38 of 39 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June 2017   
  
 
 
17 REFERENCES  
 
1. Bill-Axelson  A, Holmberg  L, Ruutu  M, Garmo  H, Stark  JR, Busch  C, et al. Radical  
prostatectomy  versus  watchful  waiting  in early  prostate cancer.  N Engl J Med 
2011;364(18):1708 -17. PUBMED  ID: 21542742  
2. Jones  CU, Hunt  D, McGowan  DG, Amin  MB, Chetner  MP, Bruner  DW,  et al. Radiotherapy  and 
short -term androgen  deprivation  for localized  prostate  cancer.  N Engl J Med 2011;365(2):107 -18. 
PUBMED  ID: 21751904  
3. Horwitz  EM, Bae K, Hanks  GE, Porter  A, Grignon  DJ, Brereton  HD, et al. Ten-year follow -up of 
radiation  therapy  oncology  group  protocol  92-02: a phase  III trial of the duration  of elective  
androgen  deprivation  in locally  advanced  prostate  cancer.  J Clin Oncol  2008;26(15):2497 -504. 
PUBMED  ID: 18413638  
4. NCCN.  National Comprehensive  Cancer  Network  Clinical  Practice  Guidelines  in Oncology:  
Prostate  Cancer.  In; 2012.  
(http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site)  
5. Schuster  DM, Savir -Baruch  B, Nieh  PT, Master  VA, Halkar  RK, Rossi  PJ, et al. Detection  of 
recurrent  prostate  carcinoma  with anti-1-amino -3-18F-fluorocyclobutane -1-carboxylic  acid 
PET/CT  and 111In -capromab  pendetide  SPECT/CT.  Radiology  2011;259(3):852 -61. PUBMED  
ID: 21493787  
6. Schuster  DM, Votaw  JR, Nieh  PT, Yu W, Nye JA, Master  V, et al. Initial  experience  with the 
radiotracer  anti-1-amino -3-18F-fluorocyclobutane -1-carboxylic  acid with PET/CT  in prostate  
carcinoma.  J Nucl  Med 2007;48(1):56 -63. PUBMED  ID: 17204699  
7. Schuster  DM, Nieh  PT, Jani AB,  Amzat  R, DuBois  Bowman  F, Halkar  RK, Master  VA, Nye JA, 
Odewole  OA, Osunkoya  AO, Savir -Baruch  B, Alaei -Taleghani  P, Goodman  MM.  Anti-3- 
[18F]FACBC  positron  emission  tomography -computerized  tomography  and 111In -capromab - 
pendetide  single  photon  emission  computerized  tomography -computerized  tomography  in 
recurrent  prostate  carcinoma:  results  of a prospective  clinical  trial. J Urology  2014;  191(5):1446 - 
1453.  
8. McParland  BJ, Wall  A, Johansson  S and Sorensen  J. The clinical  safety,  biodistribution  and 
internal  radiation  dosimetry  of [(18)F]fluciclovine  in healthy  adult  volunteers.  Eur J Nucl  Med 
Mol Imaging  2013;40:1256 -1264.  
9. Nye JA, Schuster  DM, Yu W et al. Biodistribution  and radiation  dosimetry  of the synthetic  
nonmetabolized  amino  acid analogue  anti-18F-FACBC  in humans.  J Nucl  Med 2007;48:1017 - 
1020.  
10. SNMMI NMCTG  Fluciclovine  (18F) Consensus  Reader  Meeting  Report.  2014.  
11. Odewole  OA, Jani AB, Tade  F, Nieh  PT, Master  VA, Bellamy  LM, Goodman  MM,  Raghuveer  
H, and Schuster  DM. Change  in salvage  radiotherapy  management  based  on guidance  with anti- 
3-[18F]  FACBC  PET-CT in recurrent  prostate  cancer  patients  post-prostatectomy.  In Society  of 
Nuclear  Medicine  Annual  Meeting  Abstracts,  vol. 56, Supplement  3, p. 457. 2015.  
12. Pepe,  MS. The Statistical  Evaluation  of Medical  Tests  for Classification  and Prediction.  Oxford  
University  Press.  2003.  
 
 LOCATE  39 of 39 
 
 
 
Appendix  1: Schedule  of Events  
 
 Visit  1 - 
Screen  
up to 30 
days  before  
Visit  2 Document  
Initial  
Management  
Plan Visit  2 - Day of 18F-fluciclovine  PET/CT  Visit  3 Document  
Post   18F- 
Fluciclovine  
PET/CT  
Management  
Plan End of Study  
Pre-dose/  
pre-scan Immed. 
post scan  60 min 
post dose 120 min 
post dose 
Study  Day -30 to Visit 2 Prior  to Visit 2 1 2 2-22 180 ± 28 days 
 
Visit  Location/Type  Treating  
Physician  
Office   
NA  
PET/CT  Imaging  Center  Phone  
Call  
NA  
NA 
Assessments/Procedures   
Informed  consent  X         
Inclusion/  exclusion  criteria  X  X       
Medical  history  X  X       
PCa history,  including treatment  X         
Record  PSA levels  1 X        X 
Record  imaging  studies  2 X        X 
Vital signs  (heart  rate and blood  
pressure)  X  X X X X    
Height,  weight    X       
Serum  chemistry  and hematology  X   X 3    
Serum  PSA X         
Urinalysis,  dipstick  X4         
EKG   X X 3    
Record  biopsy  results,  if applicable          X 
Injection  site assessment    X X X X X   
AE assessment     X X X X  X 
Concomitant  medication  assessment  X  X      X 
Document  management/plan   Plan      Revised  Actual  
Treatment  response  assessment          X 
1 - Record  all available  PSA levels  obtained  prior to Visit  1 through End of Study;  for non-prostectomy  subjects,  the PSA nadir  and 2 times over nadir  result  must  be documented  in the record.   
2 - Record  all available  imaging  studies  performed prior to Visit  1 through End  of Study;  negative or equivocal  imaging  within  60 days of Visit 1. 
3 - Post-dose blood  tests and EKG may be performed  at the Imaging  Center or within  7 days of the scan  at another  laboratory/site.  4May be collected and tested at any time between screening and scan date  
  
 
 
 
 
CONFIDENTIAL  Blue Earth  Diagnostics  Protocol  BED003  Version  4.0 Version  Date: 07 June  2017  